<![CDATA[Novo Nordisk A/S - Stock Exchange Announcements]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>On 2 May 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement No 33 / 2012

]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>As part of the execution of Novo Nordisk A/S' DKK 12 billion share repurchase programme for a 12-month period starting 2 February 2012, a new share repurchase programme has been initiated in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

 Company Announcement No 32 / 2012

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S purchases B shares worth DKK 4.2 billion from Novo A/S as part of the ongoing share repurchase programme]]>Novo Nordisk A/S has today entered into an agreement to purchase 5,100,000 B shares (nominal DKK 1) of a value of DKK 4.2 billion from Novo A/S as part of the ongoing DKK 12.0 billion share repurchase programme for a 12 month period beginning 2 February 2012. The transaction price is set to DKK 823.11 per share and has been calculated as the average market price from 27 April to 1 May in the open trading window following the announcement of Novo Nordisk's financial results for the first quar (...)

]]><![CDATA[Novo Nordisk A/S: Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2012]]>In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Further information:

 Company Announcement No 30 / 2012

]]><![CDATA[Novo Nordisk A/S expects to elect new chairman in 2013]]>In a press release today, the Novo Nordisk Foundation announced that the current chairman of the Board of Novo Nordisk A/S, Sten Scheibye, has been elected to the Board of the Novo Nordisk Foundation with a view to becoming its chairman in 2013.

Further information:

Company Announcement No 29 / 2012

]]><![CDATA[Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012]]>Sales growth of 13% driven by Victoza®, NovoRapid® and Levemir®

Sales increased by 13% to 17.8 billion in Danish kroner and by 10% in local currencies.

  • Sales of modern insulins increased by 17% (14% in local currencies).
  • Sales of Victoza® increased by 81% (76% in local currencies).
  • Sales in North America increased by 21% (17% in local currencies).
  • Sales in International Operations increased by 24% (24% in local currencies).

Gross margin improved by 0.7 percentage points in Danis (...)

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

 Company Announcement No 27 / 2012

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Reduction of the share capital]]>At Novo Nordisk's Annual General Meeting on 21 March 2012, it was decided to reduce the company's B share capital from DKK 472,512,800 to DKK
452,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 20,000,000 divided into 20,000,000 B shares of DKK 1 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 20,000,000 B shares. After the reduc (...)

]]><![CDATA[Novo Nordisk A/S: US Supreme Court ruling allows Caraco Pharmaceutical to challenge Novo Nordisk's patent submissions for Prandin® (repaglinide)]]>Today, Novo Nordisk announced that the US Supreme Court has reversed the US Court of Appeals for the Federal Circuit's April 2010 decision. That decision dismissed generic manufacturer Caraco Pharmaceutical's claim to change Novo Nordisk's patent submissions regarding the combination use of repaglinide and metformin for the treatment of type 2 diabetes.

Further information:


Company Announcement No 25 / 2012]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>eadOn 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 24 / 2012   

]]><![CDATA[Novo Nordisk A/S : Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 23 / 2012

 

 

 

 

]]><![CDATA[Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia®]]>Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

 

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin).

Further information:

 (...)]]><![CDATA[Novo Nordisk A/S : Status regarding Novo Nordisk's holding of its own shares (31 March 2012)]]>In continuation of the company's announcements dated 2 November 2011 and 2 February 2012 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2012 owned 27,329,627 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 27,329,627 or 4.71% of the total share capital.

 (...)]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

 

Company Announcement no 20 / 2012

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 19 / 2012

]]><![CDATA[Novo Nordisk A/S: Resolutions from the Annual General Meeting of Novo Nordisk A/S]]>Today, 21 March 2012, Novo Nordisk A/S held the Annual General Meeting at Radisson Blu Falconer Hotel & Conference Center, Falkoner Allé 9, DK-2000 Frederiksberg, Denmark.

Further information:

Company Announcement no 18 / 2012

 

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 17 / 2012

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company Announcement no 16 / 2012   

]]><![CDATA[Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

Company announcement no 15 / 2012

]]><![CDATA[Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme]]>On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Further information:

 
Company Announcement no 14 / 2012

]]>